Filtered By:
Vaccination: Cancer Vaccines

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 104 results found since Jan 2013.

Cancers, Vol. 11, Pages 108: Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells
eng-Chi Yen Dendritic cells (DCs) are capable of activating adaptive immune responses, or inducing immune suppression or tolerance. In the tumor microenvironment, the function of DCs is polarized into immune suppression that attenuates the effect of T cells, promoting differentiation of regulatory T cells and supporting tumor progression. Therefore, blocking negative immune regulators in DCs is considered a strategy of cancer immunotherapy. Antibodies can target molecules on the cell surface, but not intracellular molecules of DCs. The delivery of short-hairpin RNAs (shRNA) and small-interfering RNAs (siRNA) should be ...
Source: Cancers - January 17, 2019 Category: Cancer & Oncology Authors: Yao-Hua Liu I-Jeng Yeh Ming-Derg Lai Kuan-Ting Liu Po-Lin Kuo Meng-Chi Yen Tags: Review Source Type: research

SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis
Christine I. Alston1,2 and Richard D. Dix1,2* 1Department of Biology, Viral Immunology Center, Georgia State University, Atlanta, GA, United States 2Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, United States Suppressor of cytokine signaling (SOCS) proteins provide selective negative feedback to prevent pathogeneses caused by overstimulation of the immune system. Of the eight known SOCS proteins, SOCS1 and SOCS3 are the best studied, and systemic deletion of either gene causes early lethality in mice. Many viruses, including herpesviruses such as herpes simplex virus and cytomega...
Source: Frontiers in Immunology - April 10, 2019 Category: Allergy & Immunology Source Type: research

High Expression of DEPDC1 Promotes Malignant Phenotypes of Breast Cancer Cells and Predicts Poor Prognosis in Patients With Breast Cancer
In this study, the immunohistochemistry results demonstrated that DEPDC1 was high-expressed in breast cancer tissues compared with the paired adjacent normal breast tissues, and its tendency at protein level was consistent with mRNA level from TCGA data. Moreover, DEPDC1 mRNA level revealed the strongest association with poor prognosis and development in breast cancer. In vitro assays showed that DEPDC1 overexpression resulted in significant promotion of proliferation by regulating cell cycle in MCF-7 cells, whilst an opposite effect was found in the MDA-MB-231 cells with DEPDC1 deletion. Notably, further investigation ind...
Source: Frontiers in Oncology - April 11, 2019 Category: Cancer & Oncology Source Type: research

Blockage of immune checkpoint molecules increases T cell priming potential of dendritic cell vaccine.
In this study, we silenced the expression of PD-L1 in DCs and PD-1 in T cells by siRNA-loaded chitosan-dextran sulfate nanoparticles (NPs) and evaluated the DC phenotypic and functional characteristics and T cells functions following tumor antigen recognition on DCs, ex vivo. Our results showed that synthesized NPs had good physicochemical characteristics (size of 77.5 nm and zeta potential of 14.3) that was associated with efficient cellular uptake and target gene silencing. Moreover, PD-L1 silencing was associated with stimulatory characteristics of DCs. On the other hand, presentation of tumor antigens by PD-L1 negative...
Source: Immunology - October 5, 2019 Category: Allergy & Immunology Authors: Hassannia H, Ghasemi Chaleshtari M, Atyabi F, Nosouhian M, Masjedi A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Ghalamfarsa G, Sabz G, Hasanzadeh S, Yousefi M, Jadidi-Niaragh F Tags: Immunology Source Type: research

Therapeutic DNA vaccine encoding CEMIP (KIAA1199) ameliorates kidney fibrosis in obesity through inhibiting the Wnt/ β-catenin pathway
CONCLUSION: DNA vaccine targeting CEMIP/Wnt1/β-catenin pathway plays a novel strategy in nephropathy.GENERAL SIGNIFICANCE: Immune therapy might provide a new therapeutic option on nephropathy of obesity.PMID:34582938 | DOI:10.1016/j.bbagen.2021.130019
Source: Biochimica et Biophysica Acta - September 28, 2021 Category: Biochemistry Authors: Chao-Hung Chen Guan-Ming Ke Pi-Chen Lin Kun-Der Lin Source Type: research

Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
Conclusion. These results suggest that the efficacy of melanoma DC–based immunotherapy is enhanced when tumor antigen–loaded DCs used for vaccination express cPs. Trial registration. Clinicaltrials.gov NCT00672542. Funding. Duke Clinical Research Institute/Duke Translational Medicine Institute, Duke Melanoma Consortium, and Duke University Department of Surgery.
Source: Journal of Clinical Investigation - July 1, 2013 Category: Biomedical Science Authors: Jens Dannull, N. Rebecca Haley, Gary Archer, Smita Nair, David Boczkowski, Mark Harper, Nicole De Rosa, Nancy Pickett, Paul J. Mosca, James Burchette, Maria A. Selim, Duane A. Mitchell, John Sampson, Douglas S. Tyler, Scott K. Pruitt Source Type: research

PIAS1 and STAT‐3 impair the tumoricidal potential of IFN‐γ‐stimulated mouse dendritic cells generated with IL‐15
This article is protected by copyright. All rights reserved
Source: European Journal of Immunology - April 28, 2014 Category: Allergy & Immunology Authors: Neale T. Hanke, Collin J. LaCasse, Claire B. Larmonier, Darya Alizadeh, Malika Trad, Nona Janikashvili, Bernard Bonnotte, Emmanuel Katsanis, Nicolas Larmonier Tags: Regular Article Source Type: research

PIAS1 and STAT-3 impair the tumoricidal potential of IFN-γ-stimulated mouse dendritic cells generated with IL-15.
This article is protected by copyright. All rights reserved. PMID: 24777831 [PubMed - as supplied by publisher]
Source: European Journal of Immunology - April 28, 2014 Category: Allergy & Immunology Authors: Hanke NT, Lacasse CJ, Larmonier CB, Alizadeh D, Trad M, Janikashvili N, Bonnotte B, Katsanis E, Larmonier N Tags: Eur J Immunol Source Type: research

Abstract 5033: Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell
Conclusions: The findings obtained from the current study suggested that 5-FU and DTX may enhance the T cell-stimulating ability of DCs via down-regulation of PD-L1 and PD-L2 mediated by STAT3 inhibition, and that the combination therapy of DC-based cancer vaccine with these anti-cancer drugs may elicit better anti-tumor immune response than only vaccination. Citation Format: Masato Okamoto, Tomoyuki Tano, Hiroyuki Goda, Yohei Fujita, Koh-ichi Nakashiro, Hiroyuki Hamakawa. Down-regulation of PD-1 ligands by chemotherapeutic agents via inhibition of STAT3 activity enhances T cell-stimulating ability of dendritic cell. [abst...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Okamoto, M., Tano, T., Goda, H., Fujita, Y., Nakashiro, K.-i., Hamakawa, H. Tags: Immunology Source Type: research

siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8 + T cells in NOD/SCID/IL2Rg(null) mice
In conclusion, adoptive transfer of ex vivo primed MiHA-specific CD8+ T cells in combination with PD-L silenced DC vaccination, targeting MiHAs restricted to the hematopoietic system, is an interesting approach to boost GVT immunity in allo-SCT patients and thereby prevent relapse.
Source: Cancer Immunology, Immunotherapy - February 28, 2015 Category: Cancer & Oncology Source Type: research

Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer
Abstract Electroporation is a platform technology for drug and gene delivery. When applied to cell in vitro or tissues in vivo, it leads to an increase in membrane permeability for molecules which otherwise cannot enter the cell (e.g., siRNA, plasmid DNA, and some chemotherapeutic drugs). The therapeutic effectiveness of delivered chemotherapeutics or nucleic acids depends greatly on their successful and efficient delivery to the target tissue. Therefore, the understanding of different principles of drug and gene delivery is necessary and needs to be taken into account according to the specificity of their deliver...
Source: Cancer Immunology, Immunotherapy - June 12, 2015 Category: Cancer & Oncology Source Type: research

Abstract 3553: xCT is a new cancer stem cell immunotherapeutic target for breast cancer
In conclusion, this study provides a genomic characterization of mammary CSC and identifies fresh target for new and potentially effective anticancer vaccines, thus providing a new tool for the design of combined therapeutic approaches that efficaciously target both CSC and more differentiated cells in breast cancers, leading to both cancer treatment and prevention of metastases and recurrence.BIBLIOGRAPHY1. Nagano O et al., Oncogene 2013.2. Chen RS et al., Oncogene 2009.Citation Format: Marco Macagno, Stefania Lanzardo, Laura Conti, Roberto Ruiu, Raffaele A. Calogero, Federica Cavallo. xCT is a new cancer stem cell immuno...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Macagno, M., Lanzardo, S., Conti, L., Ruiu, R., Calogero, R. A., Cavallo, F. Tags: Experimental and Molecular Therapeutics Source Type: research

Current advances in self-assembled nanogels for immunotherapy.
Abstract Since nanogels (nanometer-sized gels) were developed two decades ago, they were utilized as carriers of innovative drug delivery systems. In particular, immunological drug delivery via self-assembled nanogels (self-Nanogels) owing to their nanometer size and molecular chaperon-like ability to encapsulate large biomolecules is one of the most well studied and successful applications of nanogels. In the present review, we focus on nanogel applications as immunological drug delivery systems for cancer vaccines, cytokine delivery, nasal vaccines and nucleic acid delivery, including several clinical trials. Ca...
Source: Advanced Drug Delivery Reviews - October 16, 2015 Category: Drugs & Pharmacology Authors: Tahara Y, Akiyoshi K Tags: Adv Drug Deliv Rev Source Type: research